medalphabetМедицинский алфавитMedical alphabet2078-56312949-2807ООО «Альфмед»10.33667/2078-5631-2021-37-26-31medalphabet-2410Research ArticleУРОЛОГИЯUROLOGYЛечение детей с медуллобластомой в возрастной группе старше 3 лет: современные подходы с учетом молекулярно-биологических особенностей опухолиTreatment of medulloblastoma in pediatric patients over 3 years old: modern approaches with respect to molecular and biologic tumor featureshttps://orcid.org/0000-0002-6606-3106ЗагидуллинаС. Р.ZagidullinaS. R.

Загидуллина Светлана Рустамовна, врач – детский онколог отделения онкологии и гематологии № 1

Москва

Zagidullina Svetlana R., pediatric oncologist at Dept of Oncology and Hematology No. 11

Moscow

zagidullina.lana@mail.ruЛевашовА. С.LevashovA. S.

Левашов Андрей Сергеевич, к. м. н., с. н. с. отделения онкологии и гематологии № 1

Москва

Levashov Andrey S., PhD Med, senior researcher at Dept of Oncology and Hematology No. 11

Moscow

andreyslevashov@mail.ruГригоренкоВ. А.GrigorenkoV. A.

Григоренко Василий Андреевич, зав. отделением лучевой терапии

Москва

Grigorenko Vasily A., head of Dept of Radiation Therapy

Moscow

oncogrigorenko@yandex.ruhttps://orcid.org/0000-0002-1469-2365ВалиевТ. Т.ValievT. T.

Валиев Тимур Теймуразович, д. м. н., зав. отделением онкологии и гематологии № 11; проф. кафедры детской онкологии; доцент кафедры онкологии

Москва

Valiev Timur T., DM Sci (habil.), head of Dept of Oncology and Hematology No. 11; professor at Dept of Pediatric Oncology; associate professor at Dept of Oncology

Moscow

timurvaliev@mail.ruНИИ детской онкологии и гематологии ФГБУ «НМИЦ онкологии имени Н. Н. Блохина» Минздрава РоссииРоссияPediatric Oncology and Hematology Research Institute of N. N. Blokhin National Research Cancer Center of Ministry of Health of RussiaRussian FederationНИИ детской онкологии и гематологии ФГБУ «НМИЦ онкологии имени Н. Н. Блохина» Минздрава России; ФГБОУ ДПО «Российская медицинская академия непрерывного последипломного образования; ФГАОУ ВО «Первый Московский государственный медицинский университет имени И. М. Сеченова» Минздрава России разования» Минздрава РоссииРоссияPediatric Oncology and Hematology Research Institute of N. N. Blokhin National Research Cancer Center of Ministry of Health of Russia; Federal State Funded Educational Institution of Further Professional Education «Russian Medical Academy of Continuing Professional Education» of Ministry of Health of Russia; Sechenov First Moscow State Medical University (Sechenov University) of Ministry of Health of RussiaRussian Federation202102012022037Диагностика и онкотерапия (4)2631Copyright © Загидуллина С.Р., Левашов А.С., Григоренко В.А., Валиев Т.Т., 20222022Загидуллина С.Р., Левашов А.С., Григоренко В.А., Валиев Т.Т.Zagidullina S.R., Levashov A.S., Grigorenko V.A., Valiev T.T.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.med-alphabet.com/jour/article/view/2410

Лечение медуллобластомы (МБ) у детей является сложной задачей клинической онкологии. Существующие протоколы лечения являются риск-адаптированными, и критерии прогностических групп риска постоянно дополняются по мере расширения представлений о молекулярно-биологических основах опухолевой трансформации при МБ. В настоящей статье рассмотрены современные программы лечения МБ, которые стали основой российских и международных клинических рекомендаций. Проанализированы результаты лечения МБ в зависимости от режимов химио- и лучевой терапии, наличия или отсутствия метастатического поражения, гистологического варианта и молекулярно-биологических характеристик опухоли.

Medulloblastoma (MB) treatment in pediatric patients is an open challenge in clinical oncology. Current treatment protocols are risk-adopted and risk group criteria continuously evolve by increasing data about molecular and biologic mechanisms of MB tumorogenesis. In the current issue it is reviewed modern treatment programs, which became a basis of Russian and International clinical recommendations. It is analyzed treatment results according to regimens of chemotherapy and irradiation, absence or presence of metastases, histologic variant and molecular and biologic tumor features.

медуллобластомахимиотерапиялучевая терапиялечениедетиmedulloblastomachemotherapyirradiationtreatmentchildrenReferencesДруй А. Е., Ясько Л. А., Коновалов Д. М., Эктова А. П., Валиахметова Э. Ф., Ольшанская Ю. В., Масчан А. А., Новичкова Г. А., Папуша Л. И. Определение молекулярно-генетических подгрупп медуллобластомы на основании анализа уровня экспрессии генов. Вопросы гематологии/онкологии и иммунопатологии в педиатрии. 2017; 16 (4): 85–89.Drui A. E., Yasko L. A., Konovalov D. M., Ektova A. P., Valiakhmetova E. F., Olshanskaya Yu.V., Maschan A. A., Novichkova G. A., Papusha L. I. Determination of molecular genetic subgroups of medulloblastoma based on the analysis of gene expression levels. Issues of hematology / oncology and immunopathology in pediatrics. 2017; 16 (4): 85–89.Northcott P. A., Robinson G. W., Kratz C. P., Mabbott D. J., Pomeroy S. L., Clifford S. C., Rutkowski S., Ellison D. W., Malkin D., Taylor M. D., Gajjar A., Pfister S. M. Medulloblastoma. Nature reviews disease primers. 2019; 5 (11): 1–20.Northcott P. A., Robinson G. W., Kratz C. P., Mabbott D. J., Pomeroy S. L., Clifford S. C., Rutkowski S., Ellison D. W., Malkin D., Taylor M. D., Gajjar A., Pfister S. M. Medulloblastoma. Nature reviews disease primers. 2019; 5 (11): 1–20.Кумирова Э. В. Новые подходы в диагностике опухолей центральной нервной системы у детей. Российский журнал детской гематологии и онкологии. 2017; 4 (1): 37–45.Kumirova E. V. New approaches in the diagnosis of tumors of the central nervous system in children. Russian Journal of Pediatric Hematology and Oncology. 2017; 4 (1): 37–45.Malbari F. Pediatric Neuro-Oncology. Neurologic Clinics. 2021; 39 (3): 829–845.Malbari F. Pediatric Neuro-Oncology. Neurologic Clinics. 2021; 39 (3): 829–845.Ostrom, Q.T., Patil N., Cioffi G., Waite K., Kruchko C., Barnholtz-Sloan J. S. CBTRUS Statistical Report: Primary brain and other central nervous system tumors diagnosed in the United States in 2013–2017. Neuro-Oncology. 2020; 22 (s1): 1–96.Ostrom, Q.T., Patil N., Cioffi G., Waite K., Kruchko C., Barnholtz-Sloan J. S. CBTRUS Statistical Report: Primary brain and other central nervous system tumors diagnosed in the United States in 2013–2017. Neuro-Oncology. 2020; 22 (s1): 1–96.Ostrom, Q.T., Patil N., Cioffi G., Waite K., Kruchko C., Barnholtz-Sloan J. S. Corrigendum to: CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2013–2017. Neuro-Oncology. 2020.Ostrom, Q.T., Patil N., Cioffi G., Waite K., Kruchko C., Barnholtz-Sloan J. S. Corrigendum to: CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2013–2017. Neuro-Oncology. 2020.Louis D. N., Perry A., Reifenberger G., Deimling A., FigarellaBranger D., Cavenee W. K., Ohgaki H., Wiestler O. D., Kleihues P., Ellison D. W. The 2016 World Health Organization Classification of tumors of the central nervous system: a summary. Acta Neuropathologica. 2016; 131 (6): 803–820.Louis D. N., Perry A., Reifenberger G., Deimling A., FigarellaBranger D., Cavenee W. K., Ohgaki H., Wiestler O. D., Kleihues P., Ellison D. W. The 2016 World Health Organization Classification of tumors of the central nervous system: a summary. Acta Neuropathologica. 2016; 131 (6): 803–820.Kameda-Smith M. M. Pediatric medulloblastoma in the molecular era: what are the surgical implications? Cancer and Metastasis Reviews. 2020; 39 (1): 235–243.Kameda-Smith M. M. Pediatric medulloblastoma in the molecular era: what are the surgical implications? Cancer and Metastasis Reviews. 2020; 39 (1): 235–243.Kesherwani V., Shukla M., Coulter D. W., Sharp J. G., Joshi S. S., Chaturvedi N. K. Long non-coding RNA profiling of pediatric medulloblastoma. 2020; 13 (1): 87.Kesherwani V., Shukla M., Coulter D. W., Sharp J. G., Joshi S. S., Chaturvedi N. K. Long non-coding RNA profiling of pediatric medulloblastoma. 2020; 13 (1): 87.Huang P., Guo Y-D., Zhang H-W. Identification of Hub genes in pediatric medulloblastoma by multiple-microarray analysis. Journal of Molecular Neuroscience. 2020; 70 (4): 522–531.Huang P., Guo Y-D., Zhang H-W. Identification of Hub genes in pediatric medulloblastoma by multiple-microarray analysis. Journal of Molecular Neuroscience. 2020; 70 (4): 522–531.Папуша Л. И., Друй А. Е., Ясько Л. А., Супик Ж. С., Земцова Л. В., Эктова А. П., Коновалов Д. М., Воронин К. А., Меришавян А. А., Бородина И. Д., Шапочник А. П., Белогурова М. Б., Махонин В. Б., Зайчиков А. Н., Шарапова Г. Р., Нестерова Ю. А., Тарасова Е. М., Новичкова Г. А., Карачунский А. И. Прогностическое значение молекулярно-генетических и клинических характеристик медуллобластом группы SHH. Вопросы гематологии/онкологии и иммунопатологии в педиатрии. 2018; 17 (3): 43–49.Papusha L. I., Druy A. E., Yasko L. A., Supik Zh.S., Zemtsova L. V., Ektova A. P., Konovalov D. M., Voronin K. A., Merishavyan A A.A., Borodina I. D., Shapochnik A. P., Belogurova M. B., Makhonin V. B., Zaichikov A. N., Sharapova G. R., Nesterova Yu.A., Tarasova E. M. ., Novichkova G. A., Karachunsky A. I. Predictive value of molecular genetic and clinical characteristics of SHH group medulloblastomas. Issues of hematology / oncology and immunopathology in pediatrics. 2018; 17 (3): 43–49.Sedano P., Segundo C.G-S. Real-world data for pediatric medulloblastoma: can we improve outcomes? European Journal of Pediatrics. 2021; 180 (1): 127–136.Sedano P., Segundo C.G-S. Real-world data for pediatric medulloblastoma: can we improve outcomes? European Journal of Pediatrics. 2021; 180 (1): 127–136.Reddy N., Ellison D. W., Soares B. P., Carson K. A., Huisman T. A.G.M., Patay Z. Pediatric posterior fossa medulloblastoma: the role of diffusion imaging in identifying molecular groups. 2020; 30 (4): 503–511.Reddy N., Ellison D. W., Soares B. P., Carson K. A., Huisman T. A.G.M., Patay Z. Pediatric posterior fossa medulloblastoma: the role of diffusion imaging in identifying molecular groups. 2020; 30 (4): 503–511.Sharma T., Schwalbe E. C., Williamson D., Sill M., Hovestadt V., Mynarek M., Rutkowski S., Robinson G., Gajjar A., Cavalli F., Ramaswamy V., Taylor M. D., Lindsey J. C., Hill R. M., Jager N., Korshunov A., Hicks D., Bailey S., Kool M., Chavez L., Northcott P. A., Pfister S. M., Clifford S. C. Second-generation molecular subgrouping of medulloblastoma: an international meta-analysis of Group 3 and Group 4 subtupes. Acta Neuropathologica. 2019; 138 (2): 309–326.Sharma T., Schwalbe E. C., Williamson D., Sill M., Hovestadt V., Mynarek M., Rutkowski S., Robinson G., Gajjar A., Cavalli F., Ramaswamy V., Taylor M. D., Lindsey J. C., Hill R. M., Jager N., Korshunov A., Hicks D., Bailey S., Kool M., Chavez L., Northcott P. A., Pfister S. M., Clifford S. C. Second-generation molecular subgrouping of medulloblastoma: an international meta-analysis of Group 3 and Group 4 subtupes. Acta Neuropathologica. 2019; 138 (2): 309–326.Pollack I. F., Agnihotri S., Broniscer A. Childhood brain tumors: current management, biological insights, and future directions. J Neurosurg Pediatr. 2019; 23 (3): 261–273.Pollack I. F., Agnihotri S., Broniscer A. Childhood brain tumors: current management, biological insights, and future directions. J Neurosurg Pediatr. 2019; 23 (3): 261–273.Tamilchelvan P., Boruah D. K., Gogoi B. B., Gogoi R. Role of MRI in differentiating various posterior cranial fossa space-occupying lesions using sensitive and specificity: a prospective study. 2021; 13 (7).Tamilchelvan P., Boruah D. K., Gogoi B. B., Gogoi R. Role of MRI in differentiating various posterior cranial fossa space-occupying lesions using sensitive and specificity: a prospective study. 2021; 13 (7).Zhang M., Wong S. W., Wright J. N., Toescu S., Mohammadzadeh M., Han M., Lummuns S., Wagner M. W., Yecies D., Lai H., Eghbal A., Radmanesh A., Nemelka J., Harward S., Malinzak M., Laughlin S., Perreault S., Braun K. R.M., Vossough A., Poussaint T., Goetti R., Erlt-Wagner B., Ho C. Y., Oztekin O., Ramaswamy V., Mankad K., Vitanza N. A., Cheshier S. H., Said M., Aquilina K., Thompson E., Jaku A., Grant A. G., Lober R. M., Yeom K. W. Machine assist for pediatric posterior fossa tumor diagnosis: a multinational study. Neurosurgery. 2021.Zhang M., Wong S. W., Wright J. N., Toescu S., Mohammadzadeh M., Han M., Lummuns S., Wagner M. W., Yecies D., Lai H., Eghbal A., Radmanesh A., Nemelka J., Harward S., Malinzak M., Laughlin S., Perreault S., Braun K. R.M., Vossough A., Poussaint T., Goetti R., Erlt-Wagner B., Ho C. Y., Oztekin O., Ramaswamy V., Mankad K., Vitanza N. A., Cheshier S. H., Said M., Aquilina K., Thompson E., Jaku A., Grant A. G., Lober R. M., Yeom K. W. Machine assist for pediatric posterior fossa tumor diagnosis: a multinational study. Neurosurgery. 2021.Rea J, Carissimo A, Trisciuoglio D, Illi B, Picard D, Remke M, Laneve P, Caffarelli E. Identification and Functional Characterization of Novel MYC-Regulated Long Noncoding RNAs in Group 3 Medulloblastoma. Cancers (Basel). 2021; 13 (15): 3853.Rea J, Carissimo A, Trisciuoglio D, Illi B, Picard D, Remke M, Laneve P, Caffarelli E. Identification and Functional Characterization of Novel MYC-Regulated Long Noncoding RNAs in Group 3 Medulloblastoma. Cancers (Basel). 2021; 13 (15): 3853.Chang F. C., Wong T. T., Wu K. S., Lu C. F., Weng T. W., Liang M. L., Wu C. C., Guo W. Y., Chen C. Y., Hsieh K. L. Magnetic resonance radiomics features and prognosticators in different molecular subtypes of pediatric Medulloblastoma. PLoS One. 2021; 16 (7).Chang F. C., Wong T. T., Wu K. S., Lu C. F., Weng T. W., Liang M. L., Wu C. C., Guo W. Y., Chen C. Y., Hsieh K. L. Magnetic resonance radiomics features and prognosticators in different molecular subtypes of pediatric Medulloblastoma. PLoS One. 2021; 16 (7).Gottardo N. G., Hansford J. R., McGlade J.P., Alvaro F., Ashley D. M., Bailey S., Baker D. L., Bourdeaut F., Cho Y.-J., Clay M., Clifford S. C., Cohn R. J., Cole C. H., Dallas P. B., Downie P., Doz F., Ellison D. W., Endersby R., Fisher P. G., Hassall T., Heath J. A., Hii H. L., Jones D. T.W., Junckerstorff R., Kellie S., Kool M., Kotecha R. S., Lichter P., Laughton S. J., Lee S., McCowage G., Northcott P. A., Olson J. M., Packer R. J., Pfister S. M., Pietsch P. T., Pizer B., Pomeroy S. L., Remke M., Robinson G. W., Rutkowski S., Schoep T., Shelat A. A., Stewart C. F., Sullivan M., Taylor M. D., Wainwright B., Walwyn T., Weiss W. A., Williamson D, Gajjar A. Medulloblastoma down under 2013: a report from the third annual meeting of the International Medulloblastoma Working Group. Acta Neuropathol. 2014; 127 (2): 189–201.Gottardo N. G., Hansford J. R., McGlade J.P., Alvaro F., Ashley D. M., Bailey S., Baker D. L., Bourdeaut F., Cho Y.-J., Clay M., Clifford S. C., Cohn R. J., Cole C. H., Dallas P. B., Downie P., Doz F., Ellison D. W., Endersby R., Fisher P. G., Hassall T., Heath J. A., Hii H. L., Jones D. T.W., Junckerstorff R., Kellie S., Kool M., Kotecha R. S., Lichter P., Laughton S. J., Lee S., McCowage G., Northcott P. A., Olson J. M., Packer R. J., Pfister S. M., Pietsch P. T., Pizer B., Pomeroy S. L., Remke M., Robinson G. W., Rutkowski S., Schoep T., Shelat A. A., Stewart C. F., Sullivan M., Taylor M. D., Wainwright B., Walwyn T., Weiss W. A., Williamson D, Gajjar A. Medulloblastoma down under 2013: a report from the third annual meeting of the International Medulloblastoma Working Group. Acta Neuropathol. 2014; 127 (2): 189–201.Ramaswamy V., Remke M., Adamski J., Bartels U., Tabori U., Wang X., Huang A., Hawkins C., Mabbott D., Laperriere N., Taylor M. D., Bouffet E. Medulloblastoma subgroup-specific outcomes in irradiated children: who are the true high-risk patients? Neuro-Oncology. 2015; 18 (2): 291–297.Ramaswamy V., Remke M., Adamski J., Bartels U., Tabori U., Wang X., Huang A., Hawkins C., Mabbott D., Laperriere N., Taylor M. D., Bouffet E. Medulloblastoma subgroup-specific outcomes in irradiated children: who are the true high-risk patients? Neuro-Oncology. 2015; 18 (2): 291–297.Dietzsch S, Placzek F, Pietschmann K, von Bueren AO, Matuschek C, Glück A, Guckenberger M, Budach V, Welzel J, Pöttgen C, Schmidberger H, Heinzelmann F, Paulsen F, Escudero MP, Schwarz R, Hornung D, Martini C, Grosu AL, Stueben G, Jablonska K, Dunst J, Stranzl-Lawatsch H, Dieckmann K, Timmermann B, Pietsch T, Warmuth-Metz M, Bison B, Kwiecien R, Benesch M, Gerber NU, Grotzer MA, Pfister SM, Clifford SC, von Hoff K, Klagges S, Rutkowski S, Kortmann RD, Mynarek M. Evaluation of Prognostic Factors and Role of Participation in a Randomized Trial or a Prospective Registry in Pediatric and Adolescent Nonmetastatic Medulloblastoma – A Report From the HIT 2000 Trial. Advances in Radiation Oncology. 2020; 5 (6): 1158–1169.Dietzsch S, Placzek F, Pietschmann K, von Bueren AO, Matuschek C, Glück A, Guckenberger M, Budach V, Welzel J, Pöttgen C, Schmidberger H, Heinzelmann F, Paulsen F, Escudero MP, Schwarz R, Hornung D, Martini C, Grosu AL, Stueben G, Jablonska K, Dunst J, Stranzl-Lawatsch H, Dieckmann K, Timmermann B, Pietsch T, Warmuth-Metz M, Bison B, Kwiecien R, Benesch M, Gerber NU, Grotzer MA, Pfister SM, Clifford SC, von Hoff K, Klagges S, Rutkowski S, Kortmann RD, Mynarek M. Evaluation of Prognostic Factors and Role of Participation in a Randomized Trial or a Prospective Registry in Pediatric and Adolescent Nonmetastatic Medulloblastoma – A Report From the HIT 2000 Trial. Advances in Radiation Oncology. 2020; 5 (6): 1158–1169.Clifford S. C., Lannering D., Schwalbe E. C., Hicks D., O’Toole K., Nicholson S. L., Goschzik T., Mühlen A., Figarella-Branger D., Doz F., Rutkowski S., Gustafsson G., Pietsch T. Biomarker- driven stratification of disease-risk in non-metastatic medulloblastoma: Results from the multi-center HIT-SIOPPNET4 clinical trial. Oncotarget. 2015; 6 (36): 38827–38839.Clifford S. C., Lannering D., Schwalbe E. C., Hicks D., O’Toole K., Nicholson S. L., Goschzik T., Mühlen A., Figarella-Branger D., Doz F., Rutkowski S., Gustafsson G., Pietsch T. Biomarker- driven stratification of disease-risk in non-metastatic medulloblastoma: Results from the multi-center HIT-SIOPPNET4 clinical trial. Oncotarget. 2015; 6 (36): 38827–38839.Lannering B., Rutkowski S., Doz F., Pizer B., Gustafsson G., Navajas A., Massimino M., Reddingius R., Benesch M., Carrie C., Taylor R., Gandola L., Bjork-Eriksson T., Giralt J., Oldenburger F., Pietsch T., Figarella-Branger D., Robson K., Forni M., Clifford S. C., Warmuth-Metz M., Hoff K., Faldum A., Mosseri V., Kortmann R. Hyperfractionated versus conventional radiotherapy followed by chemotherapy in standard-risk medulloblastoma: results from the randomized multicenter HIT-SIOP PNET 4 Trial. Journal of clinical oncology. 2012; 30 (26): 3187–3193.Lannering B., Rutkowski S., Doz F., Pizer B., Gustafsson G., Navajas A., Massimino M., Reddingius R., Benesch M., Carrie C., Taylor R., Gandola L., Bjork-Eriksson T., Giralt J., Oldenburger F., Pietsch T., Figarella-Branger D., Robson K., Forni M., Clifford S. C., Warmuth-Metz M., Hoff K., Faldum A., Mosseri V., Kortmann R. Hyperfractionated versus conventional radiotherapy followed by chemotherapy in standard-risk medulloblastoma: results from the randomized multicenter HIT-SIOP PNET 4 Trial. Journal of clinical oncology. 2012; 30 (26): 3187–3193.Kennedy C., Bull K., Chevignard M., Culliford D., Dörr H. G., Doz F., Kortmann R., Lannering B., Massimino M., Gutierrez A. N., Rutkowski S., Spoudeas, Helen A., Calaminus G. Quality of survival and growth in children and young adults in the PNET4 European controlled trial of hyperfractionated versus conventional radiation therapy for standard-risk medulloblastoma. International journal of radiation oncology, biology, physics. 2014; 88 (2); 292–300.Kennedy C., Bull K., Chevignard M., Culliford D., Dörr H. G., Doz F., Kortmann R., Lannering B., Massimino M., Gutierrez A. N., Rutkowski S., Spoudeas, Helen A., Calaminus G. Quality of survival and growth in children and young adults in the PNET4 European controlled trial of hyperfractionated versus conventional radiation therapy for standard-risk medulloblastoma. International journal of radiation oncology, biology, physics. 2014; 88 (2); 292–300.Kortmann RD. Die Chemotherapiesequenz vor oder nach Strahlentherapie hat keinen Einfluss auf das Überleben der Kinder mit Hochrisiko-Medulloblastomen: Ergebnisse der multizentrischen und randomisierten Studie der Pediatric Oncology Group (POG 9031) [The chemotherapy before or after radiation therapy does not influence survival of children with high-risk medulloblastomas: results of the multicenter and randomized study of the Pediatric Oncology Group (POG 9031)]. Strahlenther Onkol. 2014; 190 (1): 106–8.Kortmann RD. Die Chemotherapiesequenz vor oder nach Strahlentherapie hat keinen Einfluss auf das Überleben der Kinder mit Hochrisiko-Medulloblastomen: Ergebnisse der multizentrischen und randomisierten Studie der Pediatric Oncology Group (POG 9031) [The chemotherapy before or after radiation therapy does not influence survival of children with high-risk medulloblastomas: results of the multicenter and randomized study of the Pediatric Oncology Group (POG 9031)]. Strahlenther Onkol. 2014; 190 (1): 106–8.Tarbell N. J., Friedman H., Polkinghorn W. R., Yock T., Zhou T., Chen Z., Burger P., Barnes P., Kun L. High-risk medulloblastoma: a pediatric oncology group randomized trial of chemotherapy before or after radiation therapy (POG 9031). J Clin Oncol. 2013; 31 (23): 2936–2941.Tarbell N. J., Friedman H., Polkinghorn W. R., Yock T., Zhou T., Chen Z., Burger P., Barnes P., Kun L. High-risk medulloblastoma: a pediatric oncology group randomized trial of chemotherapy before or after radiation therapy (POG 9031). J Clin Oncol. 2013; 31 (23): 2936–2941.Bueren A. O., Kortmann R.-D., Hoff K., Friedrich C., Mynarek M., Muller K., Goschzik T., Muhlen A., Gerber N., Warmuth-Metz M., Soerensen N., Deinlein F., Benesch M., Zwiener I., Kwiecien R., Faldum A., Bode U., Fleischhack G., Hovestadt V., Kool M., Jones D., Northcott P., Kuehl J., Pfister S., Pietsch T., Rutkowski S. Treatment of children and adolescents with metastatic medulloblastoma and prognostic relevance of clinical and biologic parameters. J Clin Oncol. 2016; 34 (34): 4151–4159.Bueren A. O., Kortmann R.-D., Hoff K., Friedrich C., Mynarek M., Muller K., Goschzik T., Muhlen A., Gerber N., Warmuth-Metz M., Soerensen N., Deinlein F., Benesch M., Zwiener I., Kwiecien R., Faldum A., Bode U., Fleischhack G., Hovestadt V., Kool M., Jones D., Northcott P., Kuehl J., Pfister S., Pietsch T., Rutkowski S. Treatment of children and adolescents with metastatic medulloblastoma and prognostic relevance of clinical and biologic parameters. J Clin Oncol. 2016; 34 (34): 4151–4159.Michiels E. M.C., Schouten-Van Meeteren A. Y.N., Doz F., Janssens G. O., van Dalen E. C. Chemotherapy for children with medulloblastoma (Review). Cochrane Database Syst Rev. 2015.Michiels E. M.C., Schouten-Van Meeteren A. Y.N., Doz F., Janssens G. O., van Dalen E. C. Chemotherapy for children with medulloblastoma (Review). Cochrane Database Syst Rev. 2015.Dhall G, O’Neil SH, Ji L, Haley K, Whitaker AM, Nelson MD, Gilles F, Gardner SL, Allen JC, Cornelius AS, Pradhan K, Garvin JH, Olshefski RS, Hukin J, Comito M, Goldman S, Atlas MP, Walter AW, Sands S, Sposto R, Finlay JL. Excellent outcome of young children with nodular desmoplastic medulloblastoma treated on «Head Start» III: a multi-institutional, prospective clinical trial. Neuro Oncology. 2020; 22 (12): 1862–1872.Dhall G, O’Neil SH, Ji L, Haley K, Whitaker AM, Nelson MD, Gilles F, Gardner SL, Allen JC, Cornelius AS, Pradhan K, Garvin JH, Olshefski RS, Hukin J, Comito M, Goldman S, Atlas MP, Walter AW, Sands S, Sposto R, Finlay JL. Excellent outcome of young children with nodular desmoplastic medulloblastoma treated on «Head Start» III: a multi-institutional, prospective clinical trial. Neuro Oncology. 2020; 22 (12): 1862–1872.Michalski J. M., Janss A., Vesina G., Gajjar A., Pollack I., Merchant T. E., FitzGerald T. J., Booth T., Tarbell N. J., Li Y., Billups C. A., Perkins S. M., Timmerman R. D., Cherlow J. M., Packer R. Results of COG ACNS 0331: A Phase III Trial of Involved-Field Radiotherapy (IFRT) and Low Dose Craniospinal Irradiation (LD-CSI) with Chemotherapy in Average-Risk Medulloblastoma: A Report from the Children’s Oncology Group. International journal of radiation oncology. 2016; 96 (5): 937–938.Michalski J. M., Janss A., Vesina G., Gajjar A., Pollack I., Merchant T. E., FitzGerald T. J., Booth T., Tarbell N. J., Li Y., Billups C. A., Perkins S. M., Timmerman R. D., Cherlow J. M., Packer R. Results of COG ACNS 0331: A Phase III Trial of Involved-Field Radiotherapy (IFRT) and Low Dose Craniospinal Irradiation (LD-CSI) with Chemotherapy in Average-Risk Medulloblastoma: A Report from the Children’s Oncology Group. International journal of radiation oncology. 2016; 96 (5): 937–938.Lv M., Zhou M., Shpanskaya K., Perreault S., Wang Z., Tranvinh E., Lanzman B., Vajapeyam S., Vitanza N. A., Fisher P. G., Cho Y. J., Laughlin S., Ramaswamy V., Taylor M. D., Cheshier S. H., Grant G. A., Young Poussaint T., Gevaert O., Yeom K. W. MR Imaging-based radiomic signatures of distinct molecular subgroups of medulloblastoma. AJNR Am J Neuroradiol. 2019; 40 (1): 154–161.Lv M., Zhou M., Shpanskaya K., Perreault S., Wang Z., Tranvinh E., Lanzman B., Vajapeyam S., Vitanza N. A., Fisher P. G., Cho Y. J., Laughlin S., Ramaswamy V., Taylor M. D., Cheshier S. H., Grant G. A., Young Poussaint T., Gevaert O., Yeom K. W. MR Imaging-based radiomic signatures of distinct molecular subgroups of medulloblastoma. AJNR Am J Neuroradiol. 2019; 40 (1): 154–161.Packer J., Gajjar A., Vezina G., Rorke-Adams L., Burger P. C., Robertson P. L., Bayer L., LaFond D., Donahue B. R., Marymont M. H., Muraszko K., Langston J., Sposto R. Phase III Study of craniospinal radiation therapy followed by adjuvant chemotherapy for newly diagnosed average-risk medulloblastoma. J Clin Oncol. 2006; 24 (25): 4302–4208.Packer J., Gajjar A., Vezina G., Rorke-Adams L., Burger P. C., Robertson P. L., Bayer L., LaFond D., Donahue B. R., Marymont M. H., Muraszko K., Langston J., Sposto R. Phase III Study of craniospinal radiation therapy followed by adjuvant chemotherapy for newly diagnosed average-risk medulloblastoma. J Clin Oncol. 2006; 24 (25): 4302–4208.Gajjar A., Chintagumpala M., Ashley D., Kellie S., Kun L. E., Merchant T. E., Woo S., Wheeler G., Ahern V., Krasin M. J., Fouladi M., Broniscer A., Krance R., Hale G. A., Stewart C. F., Dauser R., Sanford R. A., Fuller C., Lau C., Boyett J. M., Wallace D., Gilbertson R. J. Risk-adapted craniospinal radiotherapy followed by high-dose chemotherapy and stem-cell rescue in children with newly diagnosed medulloblastoma (St Jude Medulloblastoma‑96): long-term results from a prospective, multicentre trial. Lancet Oncol. 2006; 7 (10): 813–820.Gajjar A., Chintagumpala M., Ashley D., Kellie S., Kun L. E., Merchant T. E., Woo S., Wheeler G., Ahern V., Krasin M. J., Fouladi M., Broniscer A., Krance R., Hale G. A., Stewart C. F., Dauser R., Sanford R. A., Fuller C., Lau C., Boyett J. M., Wallace D., Gilbertson R. J. Risk-adapted craniospinal radiotherapy followed by high-dose chemotherapy and stem-cell rescue in children with newly diagnosed medulloblastoma (St Jude Medulloblastoma‑96): long-term results from a prospective, multicentre trial. Lancet Oncol. 2006; 7 (10): 813–820.Bouffet E. Management of high-risk medulloblastoma. Neurochirurgie. 2019.Bouffet E. Management of high-risk medulloblastoma. Neurochirurgie. 2019.Stewart C. F., Iacono L. C., Chintagumpala M., Kellie S. J., Ashley D., Zamboni W. C., Kirstein M. N., Fouladi M., Seele L. G., Wallace D., Houghton P. J., Gajjar A. Results of a phase II upfront window of pharmacokinetically guided topotecan in high-Risk medulloblastoma and supratentorial primitive neuroectodermal tumor. J Clin Oncol. 2004; 22 (16): 3357–3365.Stewart C. F., Iacono L. C., Chintagumpala M., Kellie S. J., Ashley D., Zamboni W. C., Kirstein M. N., Fouladi M., Seele L. G., Wallace D., Houghton P. J., Gajjar A. Results of a phase II upfront window of pharmacokinetically guided topotecan in high-Risk medulloblastoma and supratentorial primitive neuroectodermal tumor. J Clin Oncol. 2004; 22 (16): 3357–3365.Dufour C., Geoffray A., Faivre L. Prognostic relevance of clinical and molecular risk factors in children with high risk medulloblastoma treated in the French prospective trial PNET HR+5. Neuro oncology. 2016; 18 (3): 121.Dufour C., Geoffray A., Faivre L. Prognostic relevance of clinical and molecular risk factors in children with high risk medulloblastoma treated in the French prospective trial PNET HR+5. Neuro oncology. 2016; 18 (3): 121.Dufour C, Foulon S, Geoffray A, Masliah-Planchon J, Figarella-Branger D, Bernier-Chastagner V, Padovani L, Guerrini-Rousseau L, Faure-Conter C, Icher C, Bertozzi AI, Leblond P, Akbaraly T, Bourdeaut F, André N, Chappé C, Schneider P, De Carli E, Chastagner P, Berger C, Lejeune J, Soler C, Entz-Werlé N, Delisle MB. Prognostic relevance of clinical and molecular risk factors in children with high-risk medulloblastoma treated in the phase II trial PNET HR+5. Neuro Oncology. 2021; 23 (7): 1163–1172.Dufour C, Foulon S, Geoffray A, Masliah-Planchon J, Figarella-Branger D, Bernier-Chastagner V, Padovani L, Guerrini-Rousseau L, Faure-Conter C, Icher C, Bertozzi AI, Leblond P, Akbaraly T, Bourdeaut F, André N, Chappé C, Schneider P, De Carli E, Chastagner P, Berger C, Lejeune J, Soler C, Entz-Werlé N, Delisle MB. Prognostic relevance of clinical and molecular risk factors in children with high-risk medulloblastoma treated in the phase II trial PNET HR+5. Neuro Oncology. 2021; 23 (7): 1163–1172.Sabel M., Fleischhack G., Tippelt S., Gustafsson G., Doz F., Kortmann R., Massimino M., Navajas A., Hoff K., Rutkowski S., Warmuth-Metz M., Clifford S. C., Pietsch T., Pizer B., Lannering B. Relapse patterns and outcome after relapse in standard risk medulloblastoma: a report from the HIT-SIOP-PNET4 study. J Neurooncol. 2016; 129 (3): 515–524.Sabel M., Fleischhack G., Tippelt S., Gustafsson G., Doz F., Kortmann R., Massimino M., Navajas A., Hoff K., Rutkowski S., Warmuth-Metz M., Clifford S. C., Pietsch T., Pizer B., Lannering B. Relapse patterns and outcome after relapse in standard risk medulloblastoma: a report from the HIT-SIOP-PNET4 study. J Neurooncol. 2016; 129 (3): 515–524.Pfister S., Remke M., Benner A., Mendrzyk F., Toedt G., Felsberg J., Wittmann A., Devens F., Gerber N. U., Joos S., Kulozik A., Reifenberger G., Rutkowski S., Wiestler O. D., Radlwimmer B., Scheurlen W., Lichter P., Korshunov A. Outcome prediction in pediatric medulloblastoma based on DNA copy-number aberrations of chromosomes 6q and 17q and the MYC and MYCN loci. J Clin Oncol. 2009; 27 (10): 1627–1636.Pfister S., Remke M., Benner A., Mendrzyk F., Toedt G., Felsberg J., Wittmann A., Devens F., Gerber N. U., Joos S., Kulozik A., Reifenberger G., Rutkowski S., Wiestler O. D., Radlwimmer B., Scheurlen W., Lichter P., Korshunov A. Outcome prediction in pediatric medulloblastoma based on DNA copy-number aberrations of chromosomes 6q and 17q and the MYC and MYCN loci. J Clin Oncol. 2009; 27 (10): 1627–1636.Huang G.-H., Xu Q.-F., Cui Y.-H., Li N., Bian X.-W., Lv S.-Q. Medulloblastoma stem cells: promising targets in medulloblastoma therapy. Cancer Sci. 2016; 107 (5): 583–589.Huang G.-H., Xu Q.-F., Cui Y.-H., Li N., Bian X.-W., Lv S.-Q. Medulloblastoma stem cells: promising targets in medulloblastoma therapy. Cancer Sci. 2016; 107 (5): 583–589.Staal J. A., Pei Y., Rood B. R. A Proteogenomic approach to understanding MYC function in metastatic medulloblastoma tumors. Int. J. Mol. Sci. 2016; 17 (10): 1744.Staal J. A., Pei Y., Rood B. R. A Proteogenomic approach to understanding MYC function in metastatic medulloblastoma tumors. Int. J. Mol. Sci. 2016; 17 (10): 1744.Hill R., Kuijper S., Lindsey J. C., Petrie K., Schwalbe E. C., Barker K., Boult J. K.R., Williamson D., Ahmad Z., Hallsworth A., Ryan S. L., Poon E., Robinson S. P., Ruddle R., Raynaud F. I., Howell L., Kwok C., Joshi A., Nicholson S. L., Crosier S., Ellison D. W., Wharton S. B., Robson K., Michalski A., Hargrave D., Jacques T. S., Pizer B., Bailey S., Swartling F. J., Weiss W. A., Chesler L., Clifford S. C. Combined MYC and P53 defects emerge at medulloblastoma relapse and define rapidly progressive, therapeutically targetable disease. Cancer Cell. 2015; 27 (1): 72–84.Hill R., Kuijper S., Lindsey J. C., Petrie K., Schwalbe E. C., Barker K., Boult J. K.R., Williamson D., Ahmad Z., Hallsworth A., Ryan S. L., Poon E., Robinson S. P., Ruddle R., Raynaud F. I., Howell L., Kwok C., Joshi A., Nicholson S. L., Crosier S., Ellison D. W., Wharton S. B., Robson K., Michalski A., Hargrave D., Jacques T. S., Pizer B., Bailey S., Swartling F. J., Weiss W. A., Chesler L., Clifford S. C. Combined MYC and P53 defects emerge at medulloblastoma relapse and define rapidly progressive, therapeutically targetable disease. Cancer Cell. 2015; 27 (1): 72–84.Shih D. J., Northcott P. A., Remke M., Korshunov A., Ramaswamy V., Kool M., Luu B., Yao Y., Wang X., Dubuc A. M., Garzia L., Peacock J., Mack S.C, Wu X., Rolider A., Morrissy A. S., Cavalli F. M., Jones D. T., Zitterbart K., Faria C. C., Schüller U., Kren L., Kumabe T., Tominaga T., Shin R. Y., Garami M., Hauser P., Chan J. A., Robinson S., Bognár L., Klekner A., Saad A. G., Liau L. M., Albrecht S., Fontebasso A., Cinalli G., De Antonellis P., Zollo M., Cooper M. K., Thompson R. C., Bailey S., Lindsey J. C., Di Rocco C., Massimi L., Michiels E. M., Scherer S. W., Phillips J. J., Gupta N., Fan X., Muraszko K. M., Vibhakar R., Eberhart C. G., Fouladi M., Lach B., Jung S., Wechsler-Reya R.J., Fèvre-Montange M., Jouvet A., Jabado N., Pollack I. F., Weiss W. A., Lee J. Y., Cho B. K., Kim S. K., Wang K. C., Leonard J. R., Rubin J. B., Torres C., Lavarino C., Mora J., Cho Y. J., Tabori U., Olson J. M., Gajjar A., Packer R. J., Rutkowski S., Pomeroy S. L., French P. J., Kloosterhof N. K., Kros J. M., Van Meir E. G., Clifford S. C., Bourdeaut F., Delattre O, Doz F. F., Hawkins C. E., Malkin D., Grajkowska W. A., Perek-Polnik M., Bouffet E., Rutka J. T., Pfister S. M., Taylor M. D. Cytogenetic prognostification within medulloblastoma subgroups. J Clin Oncol. 2014; 32 (9): 886–896.Shih D. J., Northcott P. A., Remke M., Korshunov A., Ramaswamy V., Kool M., Luu B., Yao Y., Wang X., Dubuc A. M., Garzia L., Peacock J., Mack S.C, Wu X., Rolider A., Morrissy A. S., Cavalli F. M., Jones D. T., Zitterbart K., Faria C. C., Schüller U., Kren L., Kumabe T., Tominaga T., Shin R. Y., Garami M., Hauser P., Chan J. A., Robinson S., Bognár L., Klekner A., Saad A. G., Liau L. M., Albrecht S., Fontebasso A., Cinalli G., De Antonellis P., Zollo M., Cooper M. K., Thompson R. C., Bailey S., Lindsey J. C., Di Rocco C., Massimi L., Michiels E. M., Scherer S. W., Phillips J. J., Gupta N., Fan X., Muraszko K. M., Vibhakar R., Eberhart C. G., Fouladi M., Lach B., Jung S., Wechsler-Reya R.J., Fèvre-Montange M., Jouvet A., Jabado N., Pollack I. F., Weiss W. A., Lee J. Y., Cho B. K., Kim S. K., Wang K. C., Leonard J. R., Rubin J. B., Torres C., Lavarino C., Mora J., Cho Y. J., Tabori U., Olson J. M., Gajjar A., Packer R. J., Rutkowski S., Pomeroy S. L., French P. J., Kloosterhof N. K., Kros J. M., Van Meir E. G., Clifford S. C., Bourdeaut F., Delattre O, Doz F. F., Hawkins C. E., Malkin D., Grajkowska W. A., Perek-Polnik M., Bouffet E., Rutka J. T., Pfister S. M., Taylor M. D. Cytogenetic prognostification within medulloblastoma subgroups. J Clin Oncol. 2014; 32 (9): 886–896.Pietsch T., Schmidt R., Remke M., Korshunov A., Hovestadt V., Jones D. T.W., Felsberg J., Kaulich K., Goschzik T., Kool M., Northcott P. A., Hoff K., Bueren A. O., Friedrich C., Mynarek M., Skladny H., Fleischhack G., Taylor M. D., Cremer F., Lichter P., Faldum A., Reifenberger G., Rutkowski S., Pfister S. M. Prognostic significance of clinical, histopathological, and molecular characteristics of medulloblastomas in the prospective HIT2000 multicenter clinical trial cohort. Acta Neuropathol. 2014; 128 (1): 137–149.Pietsch T., Schmidt R., Remke M., Korshunov A., Hovestadt V., Jones D. T.W., Felsberg J., Kaulich K., Goschzik T., Kool M., Northcott P. A., Hoff K., Bueren A. O., Friedrich C., Mynarek M., Skladny H., Fleischhack G., Taylor M. D., Cremer F., Lichter P., Faldum A., Reifenberger G., Rutkowski S., Pfister S. M. Prognostic significance of clinical, histopathological, and molecular characteristics of medulloblastomas in the prospective HIT2000 multicenter clinical trial cohort. Acta Neuropathol. 2014; 128 (1): 137–149.Zhukova N., Ramaswamy V., Remke M., Pfaff E., Shih D. J.H., Martin D. C., Castelo-Branco P., Baskin B., Ray P. N., Bouffet E., Bueren A. O., Jones D. T.W., Northcott P. A., Kool M., Sturm D., Pugh T. J., Pomeroy S. L., Cho Y.-J., Pietsch T., Gessi M., Rutkowski S., Bognar L., Klekner A., Cho B.-K., Kim S.-K., Wang K.-C., Eberhart C. G., Fevre-Montange M., Fouladi M., French P. J., Kros M., Grajkowska W. A., Gupta N., Weiss W. A., Hauser P., Jabado N., Jouvet A., Jung S., Kumabe T., Lach B., Leonard J. R., Rubin J. B., Liau L. M., Massimi L., Pollack I. F., Ra Y. S., Meir E. J.V., Zitterbart K., Schuller U., Hill R. M., Lindsey J. C., Schwalbe E. C., Bailey S., Ellison D. W., Hawkins C., Malkin D., Clifford S. C., Korshunov A., Pfister S., Taylor M. D., Tabori U. Subgroup-specific prognostic implications of TP53 mutation in medulloblastoma. J Clin Oncol. 2013; 31 (23): 2927–2933.Zhukova N., Ramaswamy V., Remke M., Pfaff E., Shih D. J.H., Martin D. C., Castelo-Branco P., Baskin B., Ray P. N., Bouffet E., Bueren A. O., Jones D. T.W., Northcott P. A., Kool M., Sturm D., Pugh T. J., Pomeroy S. L., Cho Y.-J., Pietsch T., Gessi M., Rutkowski S., Bognar L., Klekner A., Cho B.-K., Kim S.-K., Wang K.-C., Eberhart C. G., Fevre-Montange M., Fouladi M., French P. J., Kros M., Grajkowska W. A., Gupta N., Weiss W. A., Hauser P., Jabado N., Jouvet A., Jung S., Kumabe T., Lach B., Leonard J. R., Rubin J. B., Liau L. M., Massimi L., Pollack I. F., Ra Y. S., Meir E. J.V., Zitterbart K., Schuller U., Hill R. M., Lindsey J. C., Schwalbe E. C., Bailey S., Ellison D. W., Hawkins C., Malkin D., Clifford S. C., Korshunov A., Pfister S., Taylor M. D., Tabori U. Subgroup-specific prognostic implications of TP53 mutation in medulloblastoma. J Clin Oncol. 2013; 31 (23): 2927–2933.Cavalli F. M.G., Remke M., Rampasek L., Peacock J., Shih D. J.H., Luu B., Garzia L., Torchia J., Nor C., Morrissy A. S., Agnihotri S., Thompson Y. Y., Kuzan-Fischer C.M., Farooq H., Isaev K., Daniels C., Cho B. K., Kim S. K., Wang K. C., Lee J. Y., Grajkowska W. A., Perek- Polnik M., Vasiljevic A., Faure-Conter C., Jouvet A., Giannini C., Nageswara Rao A. A., Li K. K.W., Ng H. K., Eberhart C. G., Pollack I. F., Hamilton R. L., Gillespie G. Y., Olson J. M., Leary S., Weiss W. A., Lach B., Chambless L. B., Thompson R. C., Cooper M. K., Vibhakar R., Hauser P., van Veelen M. C., Kros J. M., French P. J., Ra Y. S., Kumabe T., López-Aguilar E., Zitterbart K., Sterba J., Finocchiaro G., Massimino M., Van Meir E. G., Osuka S., Shofuda T., Klekner A., Zollo M., Leonard J. R., Rubin J. B., Jabado N., Albrecht S., Mora J., Van Meter T. E., Jung S., Moore A. S., Hallahan A. R., Chan J. A., Tirapelli D. P.C., Carlotti C. G., Fouladi M., Pimentel J., Faria C. C., Saad A. G., Massimi L., Liau L. M., Wheeler H., Nakamura H., Elbabaa S. K., Perezpeña-Diazconti M., Chico Ponce de León F., Robinson S., Zapotocky M., Lassaletta A., Huang A., Hawkins C. E., Tabori U., Bouffet E., Bartels U., Dirks P. B., Rutka J. T., Bader G. D., Reimand J., Goldenberg A., Ramaswamy V., Taylor M. D. Intertumoral Heterogeneity within Medulloblastoma Subgroups. Cancer Cell. 2017; 31 (6): 737–754.Cavalli F. M.G., Remke M., Rampasek L., Peacock J., Shih D. J.H., Luu B., Garzia L., Torchia J., Nor C., Morrissy A. S., Agnihotri S., Thompson Y. Y., Kuzan-Fischer C.M., Farooq H., Isaev K., Daniels C., Cho B. K., Kim S. K., Wang K. C., Lee J. Y., Grajkowska W. A., Perek- Polnik M., Vasiljevic A., Faure-Conter C., Jouvet A., Giannini C., Nageswara Rao A. A., Li K. K.W., Ng H. K., Eberhart C. G., Pollack I. F., Hamilton R. L., Gillespie G. Y., Olson J. M., Leary S., Weiss W. A., Lach B., Chambless L. B., Thompson R. C., Cooper M. K., Vibhakar R., Hauser P., van Veelen M. C., Kros J. M., French P. J., Ra Y. S., Kumabe T., López-Aguilar E., Zitterbart K., Sterba J., Finocchiaro G., Massimino M., Van Meir E. G., Osuka S., Shofuda T., Klekner A., Zollo M., Leonard J. R., Rubin J. B., Jabado N., Albrecht S., Mora J., Van Meter T. E., Jung S., Moore A. S., Hallahan A. R., Chan J. A., Tirapelli D. P.C., Carlotti C. G., Fouladi M., Pimentel J., Faria C. C., Saad A. G., Massimi L., Liau L. M., Wheeler H., Nakamur H., Elbabaa S. K., Perezpeña-Diazconti M., Chico Ponce de León F., Robinson S., Zapotocky M., Lassaletta A., Huang A., Hawkins C. E., Tabori U., Bouffet E., Bartels U., Dirks P. B., Rutka J. T., Bader G. D., Reimand J., Goldenberg A., Ramaswamy V., Taylor M. D. Intertumoral Heterogeneity within Medulloblastoma Subgroups. Cancer Cell. 2017; 31 (6): 737–754.

The authors declare that there are no conflicts of interest present.